Neo-volumab news.

Building off an earlier pilot trial, the phase 3 CheckMate-816 has announced it confirms the addition of nivolumab to neoadjuvant chemo for resectable non-small cell lung cancer improves pathologic complete response rates. | Bristol Myers Squibb 2020


  1. This is such a great resource that you are providing and you give it away for free. I love seeing blog that understand the value of providing a quality resource for free kubet


Post a Comment

Popular Posts